Scholarlink

<p>To evaluate the long-term impact of mRNA-based COVID-19 vaccination on autoantibody titers, rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), and disease control in rheumatoid arthritis (RA). RA patients with at least five visits before COVID-19 vaccination started were included and categorized by their vaccination status. Changes in RF and ACPA titers were analyzed using generalized linear mixed models to assess intra-patient trends over up to seven vaccine doses. Comparisons of autoantibody titers, seroconversion rates, and disease flares between vaccinated and non-vaccinated patients were performed using weighted generalized linear models with propensity score overlap weighting to adjust for confounding. Among 427 patients (359 vaccinated, 68 non-vaccinated), RF showed a slight but statistically significant decrease after repeated mRNA vaccinations (<i>p</i> &lt; 0.001), while ACPA remained stable (<i>p</i> = 0.325). No significant differences in RF or ACPA were observed between the vaccinated and non-vaccinated patients after covariate adjustment. RF seroconversion occurred in 19.1% of RF-negative vaccinated patients and 11.8% of non-vaccinated patients and ACPA seroconversion occurred in 8.2% of ACPA-negative vaccinated patients and 13.3% of non-vaccinated patients, showing no statistically significant difference. No significant differences were found in the number of disease flares (3.82 ± 4.05 in vaccinated, 4.73 ± 5.38 in non-vaccinated). mRNA-based COVID-19 vaccination did not lead to increased autoantibody titers, seroconversion rates, or disease flare. Instead, successive vaccine doses led to a significant RF decrease, suggesting that the mRNA vaccine has a potentially beneficial immunomodulatory effect and support the safety of repeated boosters in RA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Autoantibody and disease control stability following mRNA COVID-19 vaccination in rheumatoid arthritis: an observational cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Takayuki Fujii,
  • Koichi Murata,
  • Shuichiro Nakabo,
  • Akira Onishi,
  • Kosaku Murakami,
  • Masao Tanaka,
  • Akio Morinobu,
  • Shuichi Matsuda

摘要

To evaluate the long-term impact of mRNA-based COVID-19 vaccination on autoantibody titers, rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), and disease control in rheumatoid arthritis (RA). RA patients with at least five visits before COVID-19 vaccination started were included and categorized by their vaccination status. Changes in RF and ACPA titers were analyzed using generalized linear mixed models to assess intra-patient trends over up to seven vaccine doses. Comparisons of autoantibody titers, seroconversion rates, and disease flares between vaccinated and non-vaccinated patients were performed using weighted generalized linear models with propensity score overlap weighting to adjust for confounding. Among 427 patients (359 vaccinated, 68 non-vaccinated), RF showed a slight but statistically significant decrease after repeated mRNA vaccinations (p < 0.001), while ACPA remained stable (p = 0.325). No significant differences in RF or ACPA were observed between the vaccinated and non-vaccinated patients after covariate adjustment. RF seroconversion occurred in 19.1% of RF-negative vaccinated patients and 11.8% of non-vaccinated patients and ACPA seroconversion occurred in 8.2% of ACPA-negative vaccinated patients and 13.3% of non-vaccinated patients, showing no statistically significant difference. No significant differences were found in the number of disease flares (3.82 ± 4.05 in vaccinated, 4.73 ± 5.38 in non-vaccinated). mRNA-based COVID-19 vaccination did not lead to increased autoantibody titers, seroconversion rates, or disease flare. Instead, successive vaccine doses led to a significant RF decrease, suggesting that the mRNA vaccine has a potentially beneficial immunomodulatory effect and support the safety of repeated boosters in RA.